AbbVie Inc vs Herbalife Nutrition Ltd — how do they compare? AbbVie Inc trades at $247.37 (market cap $441.94B), while Herbalife Nutrition Ltd trades at $11.71 (market cap $1.23B). The key difference: AbbVie Inc is far larger — about 359.3× Herbalife Nutrition Ltd's market cap, and AbbVie Inc pays a 2.77% dividend while Herbalife Nutrition Ltd pays none. Which is the better fit depends on your goals.
| ABBV | HLF | |
|---|---|---|
Market Cap | $441.94B | $1.23B |
Sector | Health | Consumer Staples |
52-Week High | $263.58 | $19.96 |
52-Week Low | $197.38 | $7.75 |
Enterprise Value | $506.19B | $3.06B |
Dividend Yield | 2.77% | — |
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
HLF trades at $11.52, down 6.72% in the past 24 hours, with a bearish technical signal and mixed earnings history. The company reported Q2 2026 net sales of $1.3 billion, up 5.4% year-over-year, but missed EPS estimates. Valuation ratios appear attractive with a P/E of 7.53 and P/S of 0.24, though negative shareholder equity and high debt levels remain concerns. Recent news includes a planned CFO transition in December 2026 and inclusion in TIME's America's Best Companies list.
The outlook is cautious due to inconsistent earnings performance and a highly leveraged balance sheet, but low valuation metrics and analyst consensus leaning buy (53.84%) suggest potential upside if operational improvements and debt reduction continue. Key risks include execution challenges, competitive pressures, and sensitivity to macroeconomic conditions.
Trailing returns across standard periods
Latest headlines on both assets
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →